4D Molecular Therapeutics (FDMT) Other Accumulated Expenses (2019 - 2026)
4D Molecular Therapeutics (FDMT) reported Other Accumulated Expenses of $200000.0 for Q1 2026, up 24.22% year-over-year from $161000.0 in Q1 2025, and up 55.04% quarter-over-quarter from $129000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 8 years of Other Accumulated Expenses data on file, last reported at $200000.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $200000.0, up 24.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $200000.0 (up 24.22% YoY), and the FY2025 annual result was $129000.0, up 13.16% from the prior year.
- Other Accumulated Expenses advanced to $200000.0 in Q1 2026 per FDMT's latest filing, from $129000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $748000.0 in Q2 2022 and troughed at $45000.0 in Q1 2023.
- A 5-year average of $180411.8 and a median of $129000.0 in 2025 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses slumped 93.18% in 2023, then jumped 215.56% in 2024.
- A 5-year view of Other Accumulated Expenses shows it stood at $382000.0 in 2022, then slumped by 72.77% to $104000.0 in 2023, then advanced by 9.62% to $114000.0 in 2024, then gained by 13.16% to $129000.0 in 2025, then jumped by 55.04% to $200000.0 in 2026.
- Business Quant data shows FDMT's Other Accumulated Expenses at $200000.0 in Q1 2026, $129000.0 in Q4 2025, and $108000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Sep 30, 2025 | 108,000.00 |
| Jun 30, 2025 | 102,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | 125,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 142,000.00 |
| Dec 31, 2023 | 104,000.00 |
| Sep 30, 2023 | 163,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Mar 31, 2023 | 45,000.00 |
| Dec 31, 2022 | 382,000.00 |
| Sep 30, 2022 | 188,000.00 |
| Jun 30, 2022 | 748,000.00 |
| Mar 31, 2022 | 209,000.00 |
| Dec 31, 2021 | 1.77 Mn |
| Sep 30, 2021 | 420,000.00 |
| Jun 30, 2021 | 356,000.00 |